Stephen Mallon

Stephen Mallon, PhD, is currently a Research Analyst at Ally Bridge Group in New York, specializing in the firm's public equity strategy with a focus on investments in therapeutics. At Ally Bridge Group, Dr. Mallon conducts in-depth research and analysis on publicly traded companies within the biotechnology and therapeutics sectors, supporting the firm's investment decisions and portfolio management.

Prior to joining Ally Bridge Group in 2022, Dr. Mallon served as a Senior Research Associate at RBC Capital Markets and Chardan Capital Markets, where he covered biotechnology equities and contributed to sector research on emerging therapeutic modalities. His professional background includes substantial experience in equity research and a strong analytical focus on the healthcare and life sciences space.

Dr. Mallon holds a Bachelor of Arts in Biochemistry from Bowdoin College and earned his PhD in Microbiology from the University of Chicago, bringing deep scientific expertise to his investment research. His academic and professional experience positions him as an expert in evaluating innovative therapies and life sciences companies, particularly within the biotechnology and therapeutics asset classes.